The Evolution of Cancer Immunotherapy: From Ipilimumab to 156 FDA Approvals
When the U.S. Food and Drug Administration (FDA) approved ipilimumab for advanced melanoma in 2011, it marked a paradigm shift in oncology. Over the next fourteen years, cancer immunotherapy evolved ... Read More